Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A children's cancer group study

Journal of Clinical Oncology

Volumn 18, Issue 9, 2000, Pages 1888-1899

  Maris, John M ^a   Weiss, Matthew J ^a   Guo, Chun ^a   Gerbing, Robert B ^a   Stram, Daniel O ^a   White, Peter S ^a   Hogarty, Michael D ^a   Sulman, Erik P ^a   Thompson, Patricia M ^a   Lukens, John N ^a   Matthay, Katherine K ^a   Seeger, Robert C ^a   Brodeur, Garrett M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHILD; CHROMOSOME 1P; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY LOSS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROBLASTOMA; ONCOGENE C MYB; PHASE 3 CLINICAL TRIAL; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0034015079     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.9.1888     Document Type: Article

References (47)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics. CA Cancer J Clin 49:8-31, 1999
2. Evans AE, D'Angio GJ, Randolph JA: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 27:374-378, 1971
3. Shimada H, Chatten J, Newton W, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
4. Breslow N, McCann B: Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 31:2098-2103, 1971
5. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279, 1999
6. Brodeur G, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984
7. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
8. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-Myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:581-591, 1991
9. Look AT, Haves FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231-235, 1984
10. Fong CT, Dracopoli NC, White PS, et al: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci U S A 86:3753-3757, 1989
11. Fong CT, White PS, Peterson K, et al: Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 52:1780-1785, 1992
12. Martinsson T, Sjoberg RM, Hedborg F, et al: Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 55: 5681-5686, 1995
13. White PS, Maris JM, Beltinger C, et al: A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A 92:5520-5524, 1995
14. Maris JM, White PS, Beltinger CP, et al: Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55:4664-4669, 1995
15. Gehring M, Berthold F, Edler L, et al: The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 35:5366-5369, 1995
16. Caron H, van Sluis P, de Kraker J, et al: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225-230, 1996
17. Schleiermacher G, Delattre O, Peter M, et al: Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study. Int J Cancer 69:73-78, 1996
18. Rubie H, Delattre O, Hartmann O, et al: Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: Results of the French NBL 90 Study - Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Eur J Cancer 33:1917-1922, 1997
19. Ohtsu K, Hiyama E, Ichikawa T, et al. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1. Clin Cancer Res 3:1221-1228, 1997
20. Iolascon A, Lo Cunsolo C, Giordani L, et al: Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome. Cancer Lett 130:83-92, 1998
21. Nitschke R, Smith EI, Shochat S, et al: Localized neuroblastoma treated by surgery: A Pediatric Oncology Group Study. J Clin Oncol 6:1271-1279, 1988
22. Evans AE, Silber JH, Shpilsky A, et al: Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 14:2504-2510, 1996
23. Cheung NK, Kushner BH, LaQuaglia MP, et al: Survival from non-stage 4 neuroblastoma without cytotoxic therapy: An analysis of clinical and biological markers. Eur J Cancer 33:2117-2120, 1997
24. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
25. Matthay KK, Perez C, Seeger RC, et al: Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study. J Clin Oncol 16:1256-1264, 1998
26. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996
27. Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblasmma. N Engl J Med 324:219-226, 1991
28. Seeger RC, Wada R, Brodeur GM, et al: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271:41-49, 1988
29. Hann HW, Evans AE, Siegel SE, et al: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Children's Cancer Study Group experience. Cancer Res 45:2843-2848, 1985
30. Maris JM, Guo C, Blake D, et al: A comprehensive analysis of chromosome 1p deletions in neuroblasloma. Eur J Cancer (in press)
31. Brownstein MJ, Carpten JD, Smith JR: Modulation of non-templated nucleotide addition by Taq DNA polymerase: Primer modifications that facilitate genotyping. Biotechniques 20:1004-1010, 1996
32. White PS, Thompson PM, Seifried BA, et al: Detailed molecular analysis of 1p36 in neuroblastoma. Eur J Cancer (in press)
33. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:585-612, 1976
34. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
35. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
36. Shimada H, Stram DO, Chatten J, et al: Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87:1470-1476, 1995
37. Katzenslein HM, Bowman LC, Brodeur GM, et al: Prognostic significance of age. MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience - A Pediatric Oncology Group study. J Clin Oncol 16:2007-2017, 1998
38. Brodeur GM, Green AA, Hayes FA, et al: Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41:4678-4686, 1981
39. Brodeur GM, Fong CT: Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 41:153-174, 1989
40. Takeda O, Homma C, Maseki N, et al: There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 10:30-39, 1994
41. Schleiermacher G, Peter M, Michon J, et al: Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chromosomes Cancer 10:275-281, 1994
42. Caron H, Peter M, van Sluis P, et al: Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: One probably imprinted, another associated with N-myc amplification. Hum Mol Genet 4:535-539, 1995
43. Bown N, Cotterill S, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954-1961, 1999
44. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372, 1999
45. Brodeur GM, Maris JM, Yamashiro DJ, et al: Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19:93-101, 1997
46. Vandesompele J, Van Roy N, Van Gele M, et al: Genetic-heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 23:141-152, 1998
47. Ladenstein R, Ambros IM, Potschger U, et al: The prognostic significance of DNA di/tetraploidy in neuroblastoma. Med Pediatr Oncol 31:189, 1998 (abstr)